JF
TRML

Jump Financial’s Tourmaline Bio TRML Stock Holding History

Jump Financial’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,893
Closed -$318K – 2171
2025
Q1 		$318K Buy
+20,893
New +$335K ﹤0.01% 1266
2024
Q3 		– Sell
-27,782
Closed -$357K – 2126
2024
Q2 		$357K Buy
+27,782
New +$447K 0.01% 1297
2024
Q1 		– Sell
-14,500
Closed -$380K – 2311
2023
Q4 		$380K Buy
+14,500
New +$290K 0.01% 1209

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Jump Financial's TRML Position: Q2 2025 in Review

Jump Financial sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 20,893 shares — an estimated $318K sold.

Jump Financial first reported a position in TRML in Q4 2023 and held it in 3 quarters. The position peaked at $380K in Q4 2023. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • Jump Financial reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • Jump Financial sold 20,893 Tourmaline Bio shares in Q2 2025, an estimated $318K.
  • Jump Financial first reported a position in Tourmaline Bio in Q4 2023 and held it in 3 quarters.
  • Jump Financial's Tourmaline Bio position peaked at $380K in Q4 2023.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Jump Financial's 13F filing for Q2 2025, filed 13 Aug 2025.